Answers are grounded in this paper and cite their sources.
In vitro assay development demonstrates sensitive screening of RNA frameshifting inhibitors, highlighting a versatile tool for antiviral drug discovery.
To address the emerging need for high-throughput and sensitive methodologies in RNA-targeted drug discovery, this study developed and validated a novel biosensing platform based on time-gated Förster resonance energy transfer (TG-FRET). The highly conserved RNA pseudoknot of SARS-CoV-2 served as our model system and target, a structure that regulates the essential viral –1 programmed ribosomal frameshift (−1 PRF). We first constructed a fluorescent protein (mOrange2-mCherry)-based FRET reporter system to visualize and monitor –1 PRF efficiency in living cells. To enable high-throughput screening, we adapted the system into a TG-FRET assay. This assay was based on a HaloTag-mCherry fusion protein, in which the HaloTag moiety was site-specifically labeled with CoraFluor, a new class of macrotricyclic terbium complexes. This configuration enables homogeneous, time-gated detection directly in cell lysates, effectively eliminating interference from biomatrix autofluorescence. Using this platform, we quantified ivacaftor’s inhibition of −1 PRF (IC50 = 7.6 μM) and ruled out direct inhibition by MTDB. The established TG-FRET platform combines the precision for detecting molecular interactions with the high-throughput capability compatible with microplate operations, providing a powerful and versatile screening tool for drug discovery targeting functional RNA structures.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: